Post-Marketing Surveillance
Safety monitoring after a drug reaches the public — the phase that catches what trials are too small to see.
Approval trials enroll thousands; the public is millions. Post-marketing surveillance — MedWatch reports, registries, mandated follow-up studies, insurance-claims analyses — is how medicine watches a drug at full scale, catching rare events, long-horizon effects, and interactions trials couldn't power for.
For the GLP-1 class this phase is active and visible: anesthesia societies issuing pre-procedure guidance, gastroparesis litigation prompting formal reviews, pregnancy registries accruing. For patients the takeaway is calibration: an approved drug isn't a finished question, label updates are the system functioning rather than scandal, and a decade-old molecule like semaglutide carries a maturity of data a just-approved one cannot.
This glossary entry is general information, not medical advice, and is written to be consistent with FDA prescribing information and primary trial publications as of its last review. Always consult a licensed healthcare provider for personal medical decisions.
Questions about Post-Marketing Surveillance? Ask a doctor free.
A licensed doctor can apply this to your health history in a free telehealth consultation — booking takes about two minutes, with programs from $149/month. You're only charged after approval.
Book an Appointment